Cargando…

Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China

BACKGROUND: Given the shortage of suitable liver grafts for liver transplantation, proper use of hepatitis B core antibody-positive livers might be a possible way to enlarge the donor pool and to save patients with end-stage liver diseases. However, the safety of hepatitis B virus core antibody posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Ming, Yan, Lu-Nan, Yang, Jia-Yin, Wen, Tian-Fu, Li, Bo, Wang, Wen-Tao, Wu, Hong, Xu, Ming-Qing, Chen, Zhe-Yu, Wei, Yong-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319134/
https://www.ncbi.nlm.nih.gov/pubmed/30622380
http://dx.doi.org/10.3748/wjg.v24.i48.5525
_version_ 1783385021062578176
author Lei, Ming
Yan, Lu-Nan
Yang, Jia-Yin
Wen, Tian-Fu
Li, Bo
Wang, Wen-Tao
Wu, Hong
Xu, Ming-Qing
Chen, Zhe-Yu
Wei, Yong-Gang
author_facet Lei, Ming
Yan, Lu-Nan
Yang, Jia-Yin
Wen, Tian-Fu
Li, Bo
Wang, Wen-Tao
Wu, Hong
Xu, Ming-Qing
Chen, Zhe-Yu
Wei, Yong-Gang
author_sort Lei, Ming
collection PubMed
description BACKGROUND: Given the shortage of suitable liver grafts for liver transplantation, proper use of hepatitis B core antibody-positive livers might be a possible way to enlarge the donor pool and to save patients with end-stage liver diseases. However, the safety of hepatitis B virus core antibody positive (HBcAb(+)) donors has been controversial. Initial studies were mainly conducted overseas with relatively small numbers of HBcAb(+) liver recipients, and there are few relevant reports in the population of mainland China. We hypothesized that the safety of HBcAb(+) liver grafts is not suboptimal. AIM: To evaluate the safety of using hepatitis B virus (HBV) core antibody-positive donors for liver transplantation in Chinese patients. METHODS: We conducted a retrospective study enrolling 1071 patients who underwent liver transplantation consecutively from 2005 to 2016 at West China Hospital Liver Transplantation Center. Given the imbalance in several baseline variables, propensity score matching was used, and the outcomes of all recipients were reviewed in this study. RESULTS: In the whole population, 230 patients received HBcAb(+) and 841 patients received HBcAb negative (HBcAb(-)) liver grafts. The 1-, 3- and 5-year survival rates in patients and grafts between the two groups were similar (patient survival: 85.8% vs 87.2%, 77.4% vs 81.1%, 72.4% vs 76.7%, log-rank test, P = 0.16; graft survival: 83.2% vs 83.6%, 73.8% vs 75.9%, 70.8% vs 74.4%, log-rank test, P = 0.19). After propensity score matching, 210 pairs of patients were generated. The corresponding 1-, 3- and 5-year patient and graft survival rates showed no significant differences. Further studies illustrated that the post-transplant major complication rates and liver function recovery after surgery were also similar. In addition, multivariate regression analysis in the original cohort and propensity score-matched Cox analysis demonstrated that receiving HBcAb(+) liver grafts was not a significant risk factor for long-term survival. These findings were consistent in both HBV surface antigen-positive (HBsAg(+)) and HBsAg negative (HBsAg(-)) patients. Newly diagnosed HBV infection had a relatively higher incidence in HBsAg(-) patients with HBcAb(+) liver grafts (13.23%), in which HBV naive recipients suffered most (31.82%), although this difference did not affect patient and graft survival (P = 0.50 and P = 0.49, respectively). Recipients with a high HBV surface antibody (anti-HBs) titer (more than 100 IU/L) before transplantation and antiviral prophylaxis with nucleos(t)ide antiviral agents post-operation, such as nucleos(t)ide antiviral agents, had lower de novo HBV infection risks. CONCLUSION: HBcAb(+) liver grafts do not affect the long-term outcome of the recipients. Combined with proper postoperative antiviral prophylaxis, utilization of HBcAb(+) grafts is rational and feasible.
format Online
Article
Text
id pubmed-6319134
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-63191342019-01-08 Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China Lei, Ming Yan, Lu-Nan Yang, Jia-Yin Wen, Tian-Fu Li, Bo Wang, Wen-Tao Wu, Hong Xu, Ming-Qing Chen, Zhe-Yu Wei, Yong-Gang World J Gastroenterol Retrospective Study BACKGROUND: Given the shortage of suitable liver grafts for liver transplantation, proper use of hepatitis B core antibody-positive livers might be a possible way to enlarge the donor pool and to save patients with end-stage liver diseases. However, the safety of hepatitis B virus core antibody positive (HBcAb(+)) donors has been controversial. Initial studies were mainly conducted overseas with relatively small numbers of HBcAb(+) liver recipients, and there are few relevant reports in the population of mainland China. We hypothesized that the safety of HBcAb(+) liver grafts is not suboptimal. AIM: To evaluate the safety of using hepatitis B virus (HBV) core antibody-positive donors for liver transplantation in Chinese patients. METHODS: We conducted a retrospective study enrolling 1071 patients who underwent liver transplantation consecutively from 2005 to 2016 at West China Hospital Liver Transplantation Center. Given the imbalance in several baseline variables, propensity score matching was used, and the outcomes of all recipients were reviewed in this study. RESULTS: In the whole population, 230 patients received HBcAb(+) and 841 patients received HBcAb negative (HBcAb(-)) liver grafts. The 1-, 3- and 5-year survival rates in patients and grafts between the two groups were similar (patient survival: 85.8% vs 87.2%, 77.4% vs 81.1%, 72.4% vs 76.7%, log-rank test, P = 0.16; graft survival: 83.2% vs 83.6%, 73.8% vs 75.9%, 70.8% vs 74.4%, log-rank test, P = 0.19). After propensity score matching, 210 pairs of patients were generated. The corresponding 1-, 3- and 5-year patient and graft survival rates showed no significant differences. Further studies illustrated that the post-transplant major complication rates and liver function recovery after surgery were also similar. In addition, multivariate regression analysis in the original cohort and propensity score-matched Cox analysis demonstrated that receiving HBcAb(+) liver grafts was not a significant risk factor for long-term survival. These findings were consistent in both HBV surface antigen-positive (HBsAg(+)) and HBsAg negative (HBsAg(-)) patients. Newly diagnosed HBV infection had a relatively higher incidence in HBsAg(-) patients with HBcAb(+) liver grafts (13.23%), in which HBV naive recipients suffered most (31.82%), although this difference did not affect patient and graft survival (P = 0.50 and P = 0.49, respectively). Recipients with a high HBV surface antibody (anti-HBs) titer (more than 100 IU/L) before transplantation and antiviral prophylaxis with nucleos(t)ide antiviral agents post-operation, such as nucleos(t)ide antiviral agents, had lower de novo HBV infection risks. CONCLUSION: HBcAb(+) liver grafts do not affect the long-term outcome of the recipients. Combined with proper postoperative antiviral prophylaxis, utilization of HBcAb(+) grafts is rational and feasible. Baishideng Publishing Group Inc 2018-12-28 2018-12-28 /pmc/articles/PMC6319134/ /pubmed/30622380 http://dx.doi.org/10.3748/wjg.v24.i48.5525 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Lei, Ming
Yan, Lu-Nan
Yang, Jia-Yin
Wen, Tian-Fu
Li, Bo
Wang, Wen-Tao
Wu, Hong
Xu, Ming-Qing
Chen, Zhe-Yu
Wei, Yong-Gang
Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China
title Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China
title_full Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China
title_fullStr Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China
title_full_unstemmed Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China
title_short Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China
title_sort safety of hepatitis b virus core antibody-positive grafts in liver transplantation: a single-center experience in china
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319134/
https://www.ncbi.nlm.nih.gov/pubmed/30622380
http://dx.doi.org/10.3748/wjg.v24.i48.5525
work_keys_str_mv AT leiming safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT yanlunan safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT yangjiayin safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT wentianfu safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT libo safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT wangwentao safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT wuhong safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT xumingqing safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT chenzheyu safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina
AT weiyonggang safetyofhepatitisbviruscoreantibodypositivegraftsinlivertransplantationasinglecenterexperienceinchina